Inovio Pharmaceuticals, Inc. (INO) stock forecast & analysis
1.89
NasdaqCM · USDDelayed by 15 minutes
Up: +1.29, +213.7%
1 analysis
Latest analysis: · verdict locked
- Open
- 1.99
- Previous close
- 0.6024
- Day range
- 1.66 – 2.17
- 52-week range
- 0.5600 – 2.72
- Volume (shares)
- 222.12M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 103.40M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.73
- Market cap
- 195.42M
Market Scanner’s AI analysis of Inovio Pharmaceuticals, Inc. (INO), updated November 2026: Inovio Pharmaceuticals' recent analyses covered strong technical uptrend indicators alongside persistent operating losses and a recent net income.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Inovio Pharmaceuticals, Inc. (INO) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Inovio Pharmaceuticals' recent analyses covered strong technical uptrend indicators alongside persistent operating losses and a recent net income.
Recent analyses for Inovio Pharmaceuticals (INO) examined a significant bullish technical trend, evidenced by price levels well above key moving averages and strong short-to-medium term price changes. The reports also detailed the company's financial performance, noting consistent operating losses and net losses in recent fiscal years, though a net income was reported in the most recent fiscal year-end quarter. The upcoming earnings report was also highlighted.
INO technical picture
INO's price action showed a strong upward trend, trading significantly above its 50-day and 200-day simple moving averages. Momentum indicators, including 7-day, 30-day, and 91-day changes, reinforced this trend, while the RSI was just above the overbought threshold and the MFI was well into overbought territory.
Fundamentals
Inovio Pharmaceuticals reported consistent operating and net losses over recent fiscal years, though a net income was noted in the most recent fiscal year-end quarter. Shareholder equity was positive as of mid-2026, with total assets exceeding total liabilities.
Factors discussed — upside
- Price trading significantly above 50-day and 200-day SMAs
- Strong positive 7-day, 30-day, and 91-day price changes
- RSI indicating sustained buying pressure
- MFI well into overbought territory
Factors discussed — risks
- Consistent net losses over the past four fiscal years
- Operating losses in recent quarterly periods
- RSI just above the overbought threshold
- Technical price trends
- Financial performance
- Earnings reports
Summary updated .
INO technical indicators
Common technical indicators for INO, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.15 | Price above |
| 10-day exponential moving average | 1.04 | Price above |
| Relative strength index (14-day) | 71.44 | Overbought |
| MACD line (12/26/9) | -0.0161 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.52 – 1.50 | Price above the upper band |
Analyses
Recent INO.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-03 INO.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Inovio Pharmaceuticals, Inc.?
- The company's recent analyses highlighted a strong technical uptrend, with its stock price trading significantly above key moving averages and showing substantial short-to-medium term price increases. Technical indicators such as the RSI and MFI suggest sustained buying pressure.
- What are the risks for Inovio Pharmaceuticals, Inc.?
- The company has consistently reported net and operating losses in recent fiscal years, although a net income was observed in the most recent fiscal year-end quarter. The RSI is also noted as being just above the overbought threshold.
- Is Inovio Pharmaceuticals, Inc. bullish or bearish?
- Recent AI analyses of Inovio Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The company's recent analyses highlighted a strong technical uptrend, with its stock price trading significantly above key moving averages and showing substantial short-to-medium term price increases. Technical indicators such as the RSI and MFI suggest sustained buying pressure. Discussed risks: The company has consistently reported net and operating losses in recent fiscal years, although a net income was observed in the most recent fiscal year-end quarter. The RSI is also noted as being just above the overbought threshold. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Inovio Pharmaceuticals, Inc.?
- Recent analyses for Inovio Pharmaceuticals (INO) examined a significant bullish technical trend, evidenced by price levels well above key moving averages and strong short-to-medium term price changes. The reports also detailed the company's financial performance, noting consistent operating losses and net losses in recent fiscal years, though a net income was reported in the most recent fiscal year-end quarter. The upcoming earnings report was also highlighted.
- How does Market Scanner analyse Inovio Pharmaceuticals, Inc.?
- Every analysis of Inovio Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Inovio Pharmaceuticals, Inc.?
The company's recent analyses highlighted a strong technical uptrend, with its stock price trading significantly above key moving averages and showing substantial short-to-medium term price increases. Technical indicators such as the RSI and MFI suggest sustained buying pressure.
What are the risks for Inovio Pharmaceuticals, Inc.?
The company has consistently reported net and operating losses in recent fiscal years, although a net income was observed in the most recent fiscal year-end quarter. The RSI is also noted as being just above the overbought threshold.
Is Inovio Pharmaceuticals, Inc. bullish or bearish?
Recent AI analyses of Inovio Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The company's recent analyses highlighted a strong technical uptrend, with its stock price trading significantly above key moving averages and showing substantial short-to-medium term price increases. Technical indicators such as the RSI and MFI suggest sustained buying pressure. Discussed risks: The company has consistently reported net and operating losses in recent fiscal years, although a net income was observed in the most recent fiscal year-end quarter. The RSI is also noted as being just above the overbought threshold. These are descriptive observations, not a recommendation.
What is the latest sentiment on Inovio Pharmaceuticals, Inc.?
Recent analyses for Inovio Pharmaceuticals (INO) examined a significant bullish technical trend, evidenced by price levels well above key moving averages and strong short-to-medium term price changes. The reports also detailed the company's financial performance, noting consistent operating losses and net losses in recent fiscal years, though a net income was reported in the most recent fiscal year-end quarter. The upcoming earnings report was also highlighted.
How does Market Scanner analyse Inovio Pharmaceuticals, Inc.?
Every analysis of Inovio Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh INO.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.